Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Alzheimer's Research & Therapy
Published in: Alzheimer's Research & Therapy 1/2017

Open Access 01-12-2017 | Research

Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Authors: Carole Dufouil, Bruno Dubois, Bruno Vellas, Florence Pasquier, Frédéric Blanc, Jacques Hugon, Olivier Hanon, Jean-François Dartigues, Sandrine Harston, Audrey Gabelle, Mathieu Ceccaldi, Olivier Beauchet, Pierre Krolak-Salmon, Renaud David, Olivier Rouaud, Olivier Godefroy, Catherine Belin, Isabelle Rouch, Nicolas Auguste, David Wallon, Athanase Benetos, Jérémie Pariente, Marc Paccalin, Olivier Moreaud, Caroline Hommet, François Sellal, Claire Boutoleau-Bretonniére, Isabelle Jalenques, Armelle Gentric, Pierre Vandel, Chabha Azouani, Ludovic Fillon, Clara Fischer, Helen Savarieau, Gregory Operto, Hugo Bertin, Marie Chupin, Vincent Bouteloup, Marie-Odile Habert, Jean-François Mangin, Geneviève Chêne, on behalf of the MEMENTO cohort Study Group

Published in: Alzheimer's Research & Therapy | Issue 1/2017

Login to get access

Abstract

Background

The natural history and disease mechanisms of Alzheimer’s disease and related disorders (ADRD) are still poorly understood. Very few resources are available to scrutinise patients as early as needed and to use integrative approaches combining standardised, repeated clinical investigations and cutting-edge biomarker measurements.

Methods

In the nationwide French MEMENTO cohort study, participants were recruited in memory clinics and screened for either isolated subjective cognitive complaints (SCCs) or mild cognitive impairment (MCI; defined as test performance 1.5 SD below age, sex and education-level norms) while not demented (Clinical Dementia Rating [CDR] <1). Baseline data collection included neurological and physical examinations as well as extensive neuropsychological testing. To be included in the MEMENTO cohort, participants had to agree to undergo both brain magnetic resonance imaging (MRI) and blood sampling. Cerebral 18F-fluorodeoxyglucose positon emission tomography and lumbar puncture were optional. Automated analyses of cerebral MRI included assessments of volumes of whole-brain, hippocampal and white matter lesions.

Results

The 2323 participants, recruited from April 2011 to June 2014, were aged 71 years, on average (SD 8.7), and 62% were women. CDR was 0 in 40% of participants, and 30% carried at least one apolipoprotein E ε4 allele. We observed that more than half (52%) of participants had amnestic mild cognitive impairment (17% single-domain aMCI), 32% had non-amnestic mild cognitive impairment (16.9% single-domain naMCI) and 16% had isolated SCCs. Multivariable analyses of neuroimaging markers associations with cognitive categories showed that participants with aMCI had worse levels of imaging biomarkers than the others, whereas participants with naMCI had markers at intermediate levels between SCC and aMCI. The burden of white matter lesions tended to be larger in participants with aMCI. Independently of CDR, all neuroimaging and neuropsychological markers worsened with age, whereas differences were not consistent according to sex.

Conclusions

MEMENTO is a large cohort with extensive clinical, neuropsychological and neuroimaging data and represents a platform for studying the natural history of ADRD in a large group of participants with different subtypes of MCI (amnestic or not amnestic) or isolated SCCs.

Trial registration

Clinicaltrials.gov, NCT01926249. Registered on 16 August 2013.
Appendix
Available only for authorised users
Literature
1.
Jacqmin-Gadda H, Alperovitch A, Montlahuc C, Commenges D, Leffondre K, Dufouil C, et al. 20-Year prevalence projections for dementia and impact of preventive policy about risk factors. Eur J Epidemiol. 2013;28:493–502.CrossRefPubMed
2.
Jack Jr CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–16.CrossRefPubMedPubMedCentral
3.
Casanova R, Varma S, Simpson B, Kim M, An Y, Saldana S, et al. Blood metabolite markers of preclinical Alzheimer’s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 2016;12:815–22.CrossRefPubMedPubMedCentral
4.
Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, et al. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst). 2016;3:63–72.
5.
Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009;68:1–14.CrossRefPubMedPubMedCentral
6.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370:322–33.CrossRefPubMedPubMedCentral
7.
Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener. 2012;1:18.CrossRefPubMedPubMedCentral
8.
9.
Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362–81.CrossRefPubMedPubMedCentral
10.
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–4.CrossRefPubMed
11.
Hugonot-Diner L. MMS version consensuelle GRECO. In: La consultation en gériatrie. Paris: Masson; 2001. p. 13–20.
12.
Wechsler D. Wechsler Memory Scale. New York: Psychological Corp; 1975.
13.
Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988;38:900–3.CrossRefPubMed
14.
Barbeau E, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, et al. Evaluation of visual recognition memory in MCI patients. Neurology. 2004;62:1317–22.CrossRefPubMed
15.
16.
Deloche G, Hannequin D, Dordain M, Perrier D, Pichard B, Quint S, et al. Picture confrontation oral naming: performance differences between aphasics and normals. Brain Lang. 1996;53:105–20.CrossRefPubMed
17.
Peigneux P, Van der Liden M. Presentation d’une batterie neuropsychologique et cognitive pour l’evaluation de l’apraxie gestuelle. Rev Neuropsychol. 2000;10:311–62.
18.
Benton AL, Varney NR, Hamsher KD. Visuospatial judgment: a clinical test. Arch Neurol. 1978;35:364–7.CrossRefPubMed
19.
Reischies FM, Neu P. Comorbidity of mild cognitive disorder and depression – a neuropsychological analysis. Eur Arch Psychiatry Clin Neurosci. 2000;250:186–93.CrossRefPubMed
20.
Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol. 2004;19:203–14.CrossRefPubMed
21.
Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000;55:1621–6.CrossRefPubMed
22.
Slachevsky A, Villalpando JM, Sarazin M, Hahn-Barma V, Pillon B, Dubois B. Frontal Assessment Battery and differential diagnosis of frontotemporal dementia and Alzheimer disease. Arch Neurol. 2004;61:1104–7.CrossRefPubMed
23.
de Medeiros K, Robert P, Gauthier S, Stella F, Politis A, Leoutsakos J, et al. The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia. Int Psychogeriatr. 2010;22:984–94.CrossRefPubMedPubMedCentral
24.
Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006;9:755–62.CrossRefPubMed
25.
Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.CrossRefPubMed
26.
Lawton MP. Scales to measure competence in everyday activities. Psychopharmacol Bull. 1988;24:609–14.PubMed
27.
Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85–94.CrossRefPubMed
28.
Operto G, Chupin M, Batrancourt B, Habert MO, Colliot O, Benali H, et al. CATI: a large distributed infrastructure for the neuroimaging of cohorts. Neuroinformatics. 2016;14:253–64.CrossRefPubMed
29.
Habert MO, Marie S, Bertin H, Reynal M, Martini JB, Diallo M, et al. Optimization of brain PET imaging for a multicentre trial: the French CATI experience. EJNMMI Phys. 2016;3:6.CrossRefPubMedPubMedCentral
30.
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Nagren K, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103–10.CrossRefPubMed
31.
Prieto E, Marti-Climent JM, Arbizu J, Garrastachu P, Dominguez I, Quincoces G, et al. Evaluation of spatial resolution of a PET scanner through the simulation and experimental measurement of the recovery coefficient. Comput Biol Med. 2010;40:75–80.CrossRefPubMed
32.
Chupin M, Hammers A, Liu RS, Colliot O, Burdett J, Bardinet E, et al. Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation. Neuroimage. 2009;46:749–61.CrossRefPubMedPubMedCentral
33.
Chupin M, Mukuna-Bantumbakulu AR, Hasboun D, Bardinet E, Baillet S, Kinkingnehun S, et al. Anatomically constrained region deformation for the automated segmentation of the hippocampus and the amygdala: Method and validation on controls and patients with Alzheimer’s disease. Neuroimage. 2007;34:996–1019.CrossRefPubMed
34.
Scheltens P, Launer LJ, Barkhof F, Weinstein HC, van Gool WA. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol. 1995;242:557–60.CrossRefPubMed
35.
Fischl B, van der Kouwe A, Destrieux C, Halgren E, Segonne F, Salat DH, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11–22.CrossRefPubMed
36.
Desikan RS, Segonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968–80.CrossRefPubMed
37.
Mangin JF, Jouvent E, Cachia A. In-vivo measurement of cortical morphology: means and meanings. Curr Opin Neurol. 2010;23:359–67.PubMed
38.
Perrot M, Riviere D, Mangin JF. Cortical sulci recognition and spatial normalization. Med Image Anal. 2011;15:529–50.CrossRefPubMed
39.
Samaille T, Fillon L, Cuingnet R, Jouvent E, Chabriat H, Dormont D, et al. Contrast-based fully automatic segmentation of white matter hyperintensities: method and validation. PLoS One. 2012;7:e48953.CrossRefPubMedPubMedCentral
40.
Fazekas F, Barkhof F, Wahlund LO, Pantoni L, Erkinjuntti T, Scheltens P, et al. CT and MRI rating of white matter lesions. Cerebrovasc Dis. 2002;13 Suppl 2:31–6.CrossRefPubMed
41.
Guevara P, Duclap D, Poupon C, Marrakchi-Kacem L, Fillard P, Le Bihan D, et al. Automatic fiber bundle segmentation in massive tractography datasets using a multi-subject bundle atlas. Neuroimage. 2012;61:1083–99.CrossRefPubMed
42.
Duclap D, Lebois A, Scmitt B, Riff O, Guevara P, Marrakchi-Kacem L, et al. Connectomist-2.0: a novel diffusion analysis toolbox for BrainVISA. In: 29th ESMRMB Congress, Lisbon, Portugal, 2012.
43.
Buchert R, Wilke F, Chakrabarti B, Martin B, Brenner W, Mester J, et al. Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer’s disease. J Neuroimaging. 2005;15:348–55.CrossRefPubMed
44.
Toussaint PJ, Perlbarg V, Bellec P, Desarnaud S, Lacomblez L, Doyon J, et al. Resting state FDG-PET functional connectivity as an early biomarker of Alzheimer’s disease using conjoint univariate and independent component analyses. Neuroimage. 2012;63:936–46.CrossRefPubMed
45.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.CrossRefPubMed
46.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
47.
48.
Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage. 2009;45:1107–16.CrossRefPubMedPubMedCentral
49.
Weuve J, Proust-Lima C, Power MC, Gross AL, Hofer SM, Thiebaut R, et al. Guidelines for reporting methodological challenges and evaluating potential bias in dementia research. Alzheimers Dement. 2015;11:1098–109.CrossRefPubMedPubMedCentral
50.
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, et al. The road ahead to cure Alzheimer’s disease: development of biological markers and neuroimaging methods for prevention trials across all stages and target populations. J Prev Alzheimers Dis. 2014;1:181–202.PubMedPubMedCentral
51.
52.
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, et al. Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 2009;8:619–27.CrossRefPubMed
53.
Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785–96.CrossRefPubMedPubMedCentral
54.
Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer’s disease first symptoms are age dependent: evidence from the NACC dataset. Alzheimers Dement. 2015;11:1349–57.CrossRefPubMedPubMedCentral
55.
Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66:1151–7.CrossRefPubMedPubMedCentral
56.
Yesavage JA, O’Hara R, Kraemer H, Noda A, Taylor JL, Ferris S, et al. Modeling the prevalence and incidence of Alzheimer’s disease and mild cognitive impairment. J Psychiatr Res. 2002;36:281–6.CrossRefPubMed
57.
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385–93.CrossRefPubMed
58.
Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D. Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry. 2007;64:1443–50.CrossRefPubMedPubMedCentral
59.
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer’s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74:201–9.CrossRefPubMedPubMedCentral
60.
Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 Study: Stopping AD before Symptoms Begin. Sci Transl Med. 2014;6(228):228fs13.
Metadata
Title
Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort
Authors
Carole Dufouil
Bruno Dubois
Bruno Vellas
Florence Pasquier
Frédéric Blanc
Jacques Hugon
Olivier Hanon
Jean-François Dartigues
Sandrine Harston
Audrey Gabelle
Mathieu Ceccaldi
Olivier Beauchet
Pierre Krolak-Salmon
Renaud David
Olivier Rouaud
Olivier Godefroy
Catherine Belin
Isabelle Rouch
Nicolas Auguste
David Wallon
Athanase Benetos
Jérémie Pariente
Marc Paccalin
Olivier Moreaud
Caroline Hommet
François Sellal
Claire Boutoleau-Bretonniére
Isabelle Jalenques
Armelle Gentric
Pierre Vandel
Chabha Azouani
Ludovic Fillon
Clara Fischer
Helen Savarieau
Gregory Operto
Hugo Bertin
Marie Chupin
Vincent Bouteloup
Marie-Odile Habert
Jean-François Mangin
Geneviève Chêne
on behalf of the MEMENTO cohort Study Group
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Alzheimer's Research & Therapy / Issue 1/2017
Electronic ISSN: 1758-9193
DOI
https://doi.org/10.1186/s13195-017-0288-0

Other articles of this Issue 1/2017

Alzheimer's Research & Therapy 1/2017 Go to the issue

Research

Tau passive immunization inhibits not only tau but also Aβ pathology

Research

Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases

Research

DHA brain uptake and APOE4 status: a PET study with [1-11C]-DHA

Research

Evaluation of a DNA Aβ42 vaccine in adult rhesus monkeys (Macaca mulatta): antibody kinetics and immune profile after intradermal immunization with full-length DNA Aβ42 trimer

Research

Attitudes toward clinical trials across the Alzheimer’s disease spectrum

Research

Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression